I am currently a Postdoctoral Associate in the laboratory of Dr. David A. Harris in the Department of Biochemistry at Boston University School of Medicine. I hold a B.Sc. and M.Sc. in Biotechnology from Osmania University, India and a Ph.D. from CSIR-Indian Institute of Chemical Technology, where I studied the role of Alternatively spliced isoforms of alpha synuclein in human neurodegeneration under the guidance of Dr. Shasi V Kalivendi.
My research has focussed on understanding the pathways that lead to cell death in neurodegenerative disorders, identifying biomarkers for early detection and the development of novel therapeutics for neurodegenerative disorders. During my PhD, I characterized the mechanisms through which an alternatively spliced isoform of alpha synuclein might aggravate the disease phenotype in Parkinson’s disease. I also identified a novel isoform of alpha synuclein which is the shortest one discovered till date. I then worked with Dr. Dutta and Dr. Monks at Wayne State University as a Postdoctoral Fellow where in I worked on the development of multifunctional dopamine agonists as a treatment for Parkinson’s and Alzheimer’s disease. My tenure at Scripps Research with Dr. Davis was focussed on the development of mitochondrial based therapeutics for Alzheimer’s disease.
Currently, my research In Dr. Harris’ lab focuses on identifying the molecular mechanisms by which alpha synuclein aggregates interact with cell surface receptors including the cellular prion protein.
Representative Publications
- Yedlapudi D, Xu L, Luo D, Marsh GB, Todi SV, Dutta AK; Targeting alpha synuclein and amyloid beta proteins by a multifunctional brain penetrant dopamine D2/D3 agonist D520: Potential therapeutic application in Parkinson’s disease with dementia. Sci Rep. 2019 Dec 23;9(1):19648.
- Islas-Robles A, Yedlapudi D, Lau SS, Monks TJ, Toxicoproteomic Analysis of Poly(ADP-Ribose)-Associated Proteins Induced by Oxidative Stress in Human Proximal Tubule Cells. Toxicological Sciences, 171(1), 2019, 117–131
- Elmabruk A, Das B, Yedlapudi D, Xu L, Antonio T, Reith M, Dutta A, Design, Synthesis and Pharmacological Characterization of Carbazole Based Dopamine Agonists as Potential Symptomatic and Neuroprotective Therapeutic Agents for Parkinson’s Disease, ACS Chemical Neuroscience 2019 10 (1), 396-411
- Vinnakota RL*, Yedlapudi D*, Manda KM, Bhamidipati K, Bommakanti KT, RangaLakshmi GS, Kalivendi SV; Identification of an alternatively-spliced α-synuclein isoform that generates a 41-amino acid truncated peptide, 41-syn: Role in dopamine homeostasis. ACS Chem Neurosci. 2018 Jul 25 *Co first authors
- Yedlapudi D, Joshi G, Lou D, Todi SV, Dutta A; Inhibition of alpha-synuclein aggregation by multifunctional dopamine agonists assessed by a novel in vitro assay and an in vivo Drosophila synucleinopathy model. Sci Rep. 2016 Dec 5;6:38510
- Luo D, Sharma H, Yedlapudi D, Antonio T, Reith ME, Dutta AK; Novel multifunctional dopamine D2/D3 receptors agonists with potential neuroprotection and anti-alpha synuclein protein aggregation properties. Bioorganic and Medicinal Chemistry. November 2016; 24(21): 5088–5102
- Irfan H, Yedlapudi D, Kalivendi SV, Sampath Kumar HM; Synthesis and Biological Evaluation of 4β-[(5-substituted)-1,2,3,4-tetrazolyl] podophyllotoxins as anticancer compounds. Bioorganic and Medicinal Chemistry Letters. 2015 July15; 25(14): 2860- 2863.
- Manda KM, Yedlapudi D, Srikanth K, Sreedhar B, Kalivendi SV; The Chaperone-Like Activity of α-Synuclein Attenuates Aggregation of 112-syn: Plausible Cross-talk between Protein Isoforms in Protein Aggregation: PLoS One. 2014 Jun 3; 9(6):e98657.
- Kalivendi SV, Yedlapudi D, Hillard CJ, Kalyanaraman B; Oxidants induce alternative splicing of alpha-synuclein: Implications for Parkinson’s disease. Free Radical Biology and Medicine. 2010 Feb 1; 48(3):377-83.
- Srihari P, Sathish Reddy A, Yadav JS, Yedlapudi D, Kalivendi SV; First total synthesis and structure confirmation of diacetylenic polyol (+)-oploxyne B: Tetrahedron Letters, 2013; 54: 5616–5618.
